Bile Acids and Their Receptors are Associated with Central Nervous System Diseases

doi:10.3969/j.issn.2095-1396.2019.01.005

Abstract

Abstract:

Bile acids not only promote lipid absorption，but also regulate the body’s glycolipid metabolism and energy balance. Bile acid receptors are expressed in a variety of tissues and cells，including central neurons，microglia，and astrocytes，and have anti-inflammatory and antiapoptotic effects. It has now been found that bile acids can act directly on the brain through their receptors. Bile acids and their receptors play an important role in metabolic diseases including
diabetes，obesity，hepatobiliary diseases and other diseases，such as central nervous system diseases caused by inflammation，hepatic encephalopathy and amyotrophic lateral sclerosis. However，the study on the role of bile acids and their receptors in central nervous system has just started，and there are still many problems to be explored. This article reviews the biosynthesis and regulation of bile acids，receptor classification and characteristics，receptor agonists，signal transduction，and recent discoveries in central nervous system diseases.

Key words: bile acids, bile acid receptors, metabolic diseases, central nervous system

CLC Number:

R964

WU Xian，HONG Hao. Bile Acids and Their Receptors are Associated with Central Nervous System Diseases[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2019.01.005.

References

[1] Juan I Barrasa, Nieves Olmo, M Antonia Lizarbe, et al. Bile acids in the colon, from healthy to cytotoxic molecules [J]. Toxicology in vitro: an international journal published in association with BIBRA, 2013, 27(2):964-977.
[2] Javier del Pino, Paula Moyano, Maria Jose Anadon, et al. Acute and long-term exposure to chlorpyrifos induces cell death of basal forebrain cholinergic neurons through AChE variants alteration [J]. Toxicology, 2015, 336:1-9.
[3] David W Russell. The enzymes, regulation, and genetics of bile acid synthesis [J]. Annual Review of Biochemistry, 2003, 72(0):137-174.
[4] Schalm S W, LaRusso N F, Alan Hofmann, et al. Diurnal serum levels of primary conjugated bile acids. Assessment by specific radioimmunoassays for conjugates of cholic and chenodeoxycholic acid [J]. Gut, 1978, 19(11):1006-1014.
[5] Charles Thomas, Johan Auwerx, Kristina Schoonjans. Bile acids and the membrane bile acid receptor TGR5-connecting nutrition and metabolism [J]. Thyroid: Official J American Thyroid Association, 2008, 18(2):167-174.
[6] Mok H Y, Klaus Von Bergmann, Grundy S M. Regulation of pool size of bile acids in man [J]. Gastroenterology, 1977, 73(4 Pt 1):684-690.
[7] Bart Staels, Yehuda Handelsman, Vivian Fonseca. Bile acid sequestrants for lipid and glucose control [J]. Current Diabetes Reports, 2010, 10(1):70-77.
[8] Kazuyuki Yamagata, Hiroaki Daitoku, Yoko Shimamoto, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1 [J]. J Biological Chemistry, 2004, 279 (22):23158-65.
[9] Bo Angelin, Einarsson K, Hellstrom K, et al. Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia [J]. J Lipid Research, 1978, 19(8):1004-1016.
[10] Guo Chuan-sheng, Xie Shu-jun, Chi Zhe-xu, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome [J]. Immunity, 2016, 45 (4):944.
[11] Verena Keitel, Ralf Kubitz, Dieter Haussinger. Endocrine and paracrine role of bile acids [J]. World J Gastroenterology, 2008, 14(37):5620-5629.
[12] David P Moore, Shigeaki Kato, Xie Wen, et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor [J]. Pharmacological Reviews, 2006, 58 (4):742-759.
[13] Yuji Kawamata, Fujii Ryo, Masaki Hosoya, et al. A G protein-coupled receptor responsive to bile acids [J]. J Biological Chemistry, 2003, 278(11):9435-9440.
[14] Matthew McMillin, Gabriel Frampton, Matthew Quinn, et al. Bile acid signaling is involved in the neurological decline in a murine model of acute liver failure [J]. The American J Pathology, 2016, 186(2):312-23.
[15] Verena Keitel, Dieter Haussinger. Perspective: TGR5 (Gpbar-1) in liver physiology and disease [J]. Clinics and Research in Hepatology and Gastroenterology, 2012, 36 (5):412-419.
[16] Verena Keitel, Boris Gorg, Hans Bidmon, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain [J]. Glia, 2010, 58(15):1794-805.
[17] Natalia Yanguas-Casas, M Asuncion de la Barreda-Manso, Manuel Nieto-Sampedro, et al. TUDCA: an agonist of the bile acid receptor GPBAR1/TGR5 With Anti-inflammatory effects in microglial cells [J]. J Cellular Physiology, 2017, 232(8):2231-2245.
[18] Eva Hambruch, Shinobu Miyazaki-Anzai, Ulrike Hahn, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice [J]. The J Pharmacology and Experimental Therapeutics, 2012, 343(3):556-567.
[19] Sunder Mudaliar, Robert R Henry, Arun J Sanyal, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease [J]. Gastroenterology, 2013, 145(3):574-82 e1.
[20] Daniel Flesch, Matthias Gabler, Andreas Lill, et al. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties [J]. Bioorganic & Medicinal Chemistry, 2015, 23(13):3490-8.
[21] Adwoa Akwabi-Ameyaw, Jonathan Y Bass, Richard D Caldwell, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064 [J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18(15):4339-43.
[22] Brenton Flatt, Richard Martin, Wang Tie-lin, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) [J]. J Medicinal Chemistry, 2009, 52(4):904-907.
[23] Michael Trauner, Aliya Gulamhusein, Bilal Hameed, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis [J]. Hepatology, 2019, 70(3): 788-801.
[24] Thijs W H Pols. TGR5 in inflammation and cardiovascular disease [J]. Biochemical Society Transactions, 2014, 42(2):244-249.
[25] Jung –Ah Cho, Tae-Joo Kim, Hye-Jung Moon, et al. Cardiolipin activates antigen-presenting cells via TLR2-PI3K-PKN1-AKT/p38-NF-kB signaling to prime antigen-specific naive T cells in mice [J]. European J Immunology, 2018, 48(5):777-90.
[26] Pols T W H, Noriega L G, Nomura M, et al. The bile acid membrane receptor TGR5: a valuable metabolic target [J]. Digestive Diseases, 2011, 29(1):37-44.
[27] Kim Mertens, Andries Kalsbeek, Maarten Rene Soeters, et al. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system [J]. Frontiers in Neuroscience, 2017, 11: 617.
[28] Hayley D Ackerman, Glenn S Gerhard. Bile acids in neurodegenerative disorders [J]. Front Aging Neurosci, 2016, 22, 8:263
[29] Jeffrey Cummings, Garam Lee, Travis Mortsdorf, et al. Alzheimer's disease drug development pipeline: 2017 [J]. Alzheimer's & Dementia, 2017, 3(3):367-84.
[30] Kwangsik Nho, Alexandra Kueider-Paisley, Siamak MahmoudianDehkordi, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers [J]. Alzheimer's & Dementia : J Alzheimer's Association, 2019, 15(2):232-44.
[31] Siamak MahmoudianDehkordi, Matthias Arnold, Kwangsik Nho, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome [J]. Alzheimer's & Dementia : J Alzheimer's Association, 2019, 15(1):76-92.
[32] Susana Sola, Joana Dias Amaral, Pedro Borralho, et al. Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis [J]. Molecular Endocrinology, 2006, 20(10):2292-2303.
[33] Adrian C Lo, Zsuzsanna Callaerts-Vegh, Ana F Nunes, et al. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice [J]. Neurobiology of Disease, 2013, 50: 21-29.
[34] Rita M Ramalho, Ana F Nunes, Raquel B Dias, et al. Tauroursodeoxycholic acid suppresses amyloid beta-induced synaptic toxicity in vitro and in APP/PS1 mice [J]. Neurobiology of Aging, 2013, 34(2):551-61.
[35] Wu X, Lv Y G, Du Y F, et al. Inhibitory effect of INT-777 on lipopolysaccharide-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice [J]. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2018, 88:360-74.
[36] Wu Xian, Lv Yang-ge, Du Yi-feng, et al. Neuroprotective effects of INT-777 against Abeta1-42-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice [J]. Brain, Behavior, and Immunity, 2018, 73(09): 533-545.
[37] Mohsen Ghanbari, Sirwan Darweesh, Hans de Looper, et al. Genetic variants in microRNAs and their binding sites are associated with the risk of Parkinson disease [J]. Human Mutation, 2016, 37(3):292-300.
[38] Stewart F Graham, Nolwen L Rey, Zafer Ugur, et al. Metabolomic profiling of bile acids in an experimental model of prodromal Parkinson's disease [J]. Metabolites, 2018, 8(4):71.
[39] Chun Hong-sung, Walter C Low. Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells[J]. Toxicology, 2012, 292(2-3):105-112.
[40] Luo Yu, Hoffer Alan, Hoffer Barry, et al. Mitochondria: A therapeutic target for Parkinson's disease? [J]. International J Molecular Sciences, 2015, 16(9):20704-30.
[41] Castro-Caldas M, Carvalho A N, Rodrigues E, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease [J]. Molecular Neurobiology, 2012, 46(2):475-486.
[42] Heather J Mortiboys, Jan Aasly, Oliver Bandmann. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease [J]. Brain : J Neurology, 2013, 136 (Pt 10):3038-3050.
[43] Oliver Maier, Julia Bohm, Michael Dahm, et al. Differentiated NSC-34 motoneuron-like cells as experimental model for cholinergic neurodegeneration [J]. Neurochemistry International, 2013, 62(8):1029-1038.
[44] Charlotee Veyrat-Durebex, Philippe Corcia, Audrey Dangoumau, et al. Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis [J]. Molecular Neurobiology, 2014, 49(2):966-983.
[45] Ana Rita Vaz, Carolina Cunha, Catia Gomes, et al. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration [J]. Molecular Neurobiology, 2015, 51(3):864-877.
[46] Gareth Parry, Cecilia Rodrigues, Marcia M Aranha, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis [J]. Clinical Neuropharmacology, 2010, 33(1):17-21.
[47] Min Ju-Hong, Hong Yoon-Ho, Sung Jung-Joon, et al. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial [J]. J Korean Medical Science, 2012, 27(2):200-206.
[48] Elia A E, Lalli S, Monsurro M R, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis [J]. European J Neurology, 2016, 23(1):45-52.
[49] Christopher A Ross, Elizabeth H Aylward, Edward J Wild, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics [J]. Nature Reviews Neurology, 2014, 10(4):204-216.
[50] Cecilia Rodrigues, Stieers C L, Christopher Dirk Keene, et al. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition [J]. J Neurochemistry, 2000, 75(6):2368-2379.
[51] Keene CD, Rodrigues CM, Eich T, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease [J]. Experimental neurology, 2001, 171(2):351-60.
[52] C Dirk Keene, Cecilia M P Rodrigues, Tacjana Eich, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease [J]. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99(16):10671-10676.
[53] Cecilia Rodrigues, Stephen Spellman, Susana Sola, et al. Neuroprotection by a bile acid in an acute stroke model in the rat [J]. J Cerebral Blood Flow and Metabolism : Official J International Society of Cerebral Blood Flow and Metabolism, 2002, 22(4):463-471.
[54] Natalia Yanguas-Casas, M Asuncion de la Barreda-Manso, Manuel Nieto-Sampedro, et al. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation [J]. J Neuroinflammation, 2014, 11(1):50.
[55] Cecilia M P Rodrigues, Susana Sola, Nan Zhen-hong, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats [J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(10):6087-6092.
[56] Roger F Butterworth. Hepatic encephalopathy: a central neuroinflammatory disorder? [J]. Hepatology, 2011, 53(4):1372-1376.
[57] Matthew McMillin, Gabriel Frampton, Richard Tobin, et al. TGR5 signaling reduces neuroinflammation during hepatic encephalopathy [J]. J Neurochemistry, 2015, 135(3):565-576.